Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study

Mark A Boyd; Janaki Amin; Patrick W G Mallon; Nagalingeswaran Kumarasamy; Johan Lombaard; Robin Wood; Ploenchan Chetchotisakd; Praphan Phanuphak; Lerato Mohapi; Iskandar Azwa; Waldo H Belloso; Jean-Michel Molina; Jennifer Hoy; Cecilia L Moore; Sean Emery; David A Cooper

doi:10.1016/s2352-3018(16)30189-8

Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study

The Lancet HIV ◽

10.1016/s2352-3018(16)30189-8 ◽

2017 ◽

Vol 4 (1) ◽

pp. e13-e20 ◽

Cited By ~ 4

Author(s):

Mark A Boyd ◽

Janaki Amin ◽

Patrick W G Mallon ◽

Nagalingeswaran Kumarasamy ◽

Johan Lombaard ◽

...

Keyword(s):

Body Composition ◽

Antiretroviral Therapy ◽

Reverse Transcriptase ◽

Virological Failure ◽

Second Line ◽

Reverse Transcriptase Inhibitors ◽

First Line ◽

Open Label ◽

Therapy Regimen ◽

Metabolic Outcomes

Download Full-text

Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): a randomised, open-label, non-inferiority study

The Lancet ◽

10.1016/s0140-6736(13)61164-2 ◽

2013 ◽

Vol 381 (9883) ◽

pp. 2091-2099 ◽

Cited By ~ 106

Keyword(s):

Reverse Transcriptase ◽

Virological Failure ◽

Second Line ◽

Reverse Transcriptase Inhibitors ◽

First Line ◽

Open Label ◽

Hiv 1

Download Full-text

Faculty Opinions recommendation of Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): a randomised, open-label, non-inferiority study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718020574.793483235 ◽

2013 ◽

Author(s):

Anthony Harries

Keyword(s):

Reverse Transcriptase ◽

Virological Failure ◽

Second Line ◽

Reverse Transcriptase Inhibitors ◽

First Line ◽

Open Label ◽

Hiv 1

Download Full-text

Faculty Opinions recommendation of Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): a randomised, open-label, non-inferiority study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718020574.793481146 ◽

2013 ◽

Author(s):

J Michael Kilby

Keyword(s):

Reverse Transcriptase ◽

Virological Failure ◽

Second Line ◽

Reverse Transcriptase Inhibitors ◽

First Line ◽

Open Label ◽

Hiv 1

Download Full-text

Resistance at Virological Failure Using Boosted Protease Inhibitors Versus Nonnucleoside Reverse Transcriptase Inhibitors As First-Line Antiretroviral Therapy—Implications for Sustained Efficacy of ART in Resource-Limited Settings

The Journal of Infectious Diseases ◽

10.1093/infdis/jit112 ◽

2013 ◽

Vol 207 (suppl_2) ◽

pp. S78-S84 ◽

Cited By ~ 25

Author(s):

Andrew Hill ◽

Angela McBride ◽

A. William Sawyer ◽

Nathan Clumeck ◽

Ravindra K. Gupta

Keyword(s):

Antiretroviral Therapy ◽

Reverse Transcriptase ◽

Protease Inhibitors ◽

Virological Failure ◽

Reverse Transcriptase Inhibitors ◽

First Line ◽

Resource Limited Settings ◽

Nonnucleoside Reverse Transcriptase Inhibitors ◽

Sustained Efficacy ◽

Resource Limited

Download Full-text

Switch to second-line versus continued first-line antiretroviral therapy for patients with low-level HIV-1 viremia: An open-label randomized controlled trial in Lesotho

PLoS Medicine ◽

10.1371/journal.pmed.1003325 ◽

2020 ◽

Vol 17 (9) ◽

pp. e1003325

Author(s):

Alain Amstutz ◽

Bienvenu Lengo Nsakala ◽

Fiona Vanobberghen ◽

Josephine Muhairwe ◽

Tracy Renée Glass ◽

...

Keyword(s):

Randomized Controlled Trial ◽

Antiretroviral Therapy ◽

Controlled Trial ◽

Second Line ◽

First Line ◽

Open Label ◽

Low Level ◽

Randomized Controlled ◽

Hiv 1

Download Full-text

Impact of transmitted HIV-1 drug resistance on the efficacy of first-line antiretroviral therapy with two nucleos(t)ide reverse transcriptase inhibitors plus an integrase inhibitor or a protease inhibitor

Journal of Antimicrobial Chemotherapy ◽

10.1093/jac/dky211 ◽

2018 ◽

Vol 73 (9) ◽

pp. 2480-2484 ◽

Cited By ~ 9

Author(s):

C Spertilli Raffaelli ◽

B Rossetti ◽

L Paglicci ◽

M Colafigli ◽

G Punzi ◽

...

Keyword(s):

Drug Resistance ◽

Antiretroviral Therapy ◽

Protease Inhibitor ◽

Reverse Transcriptase ◽

Integrase Inhibitor ◽

Reverse Transcriptase Inhibitors ◽

First Line ◽

Hiv 1

Download Full-text

Induction with Lopinavir-Based Treatment Followed by Switch to Nevirapine-Based Regimen versus Non-Nucleoside Reverse Transcriptase Inhibitors-Based Treatment for First Line Antiretroviral Therapy in HIV Infected Children Three Years and Older

PLoS ONE ◽

10.1371/journal.pone.0108063 ◽

2014 ◽

Vol 9 (9) ◽

pp. e108063 ◽

Cited By ~ 1

Author(s):

Gerardo Alvarez-Uria ◽

Raghavakalyan Pakam ◽

Praveen Kumar Naik ◽

Manoranjan Midde

Keyword(s):

Antiretroviral Therapy ◽

Reverse Transcriptase ◽

Reverse Transcriptase Inhibitors ◽

First Line ◽

Nucleoside Reverse Transcriptase Inhibitors

Download Full-text

HIV Lipodystrophy in Participants Randomised to Lopinavir/Ritonavir (LPV/r) +2–3 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (N(t)RTI) or LPV/r + Raltegravir as Second-Line Antiretroviral Therapy

PLoS ONE ◽

10.1371/journal.pone.0077138 ◽

2013 ◽

Vol 8 (10) ◽

pp. e77138 ◽

Cited By ~ 11

Author(s):

Allison Martin ◽

Cecilia L. Moore ◽

Patrick W. G. Mallon ◽

Jennifer F. Hoy ◽

Sean Emery ◽

...

Keyword(s):

Antiretroviral Therapy ◽

Reverse Transcriptase ◽

Second Line ◽

Reverse Transcriptase Inhibitors ◽

Hiv Lipodystrophy ◽

Second Line Antiretroviral Therapy

Download Full-text

Early changes in bone turnover and inflammatory biomarkers and clinically significant bone mineral density loss over 48 weeks among HIV‐infected patients with virological failure of a standard first‐line antiretroviral therapy regimen in the SECOND‐LINE study

HIV Medicine ◽

10.1111/hiv.12882 ◽

2020 ◽

Vol 21 (8) ◽

pp. 492-504

Author(s):

GE Mwasakifwa ◽

J Amin ◽

CP White ◽

JR Center ◽

A Kelleher ◽

...

Keyword(s):

Bone Mineral Density ◽

Antiretroviral Therapy ◽

Bone Turnover ◽

Inflammatory Biomarkers ◽

Second Line ◽

Mineral Density ◽

First Line ◽

Bone Mineral Density Loss ◽

Therapy Regimen ◽

Clinically Significant

Download Full-text

Drug-resistance development differs between HIV-1-infected patients failing first-line antiretroviral therapy containing nonnucleoside reverse transcriptase inhibitors with and without thymidine analogues

HIV Medicine ◽

10.1111/hiv.12044 ◽

2013 ◽

Vol 14 (9) ◽

pp. 571-577 ◽

Cited By ~ 7

Author(s):

MM Santoro ◽

C Sabin ◽

F Forbici ◽

L Bansi ◽

D Dunn ◽

...

Keyword(s):

Drug Resistance ◽

Antiretroviral Therapy ◽

Reverse Transcriptase ◽

Reverse Transcriptase Inhibitors ◽

First Line ◽

Resistance Development ◽

Nonnucleoside Reverse Transcriptase Inhibitors ◽

Hiv 1

Download Full-text